Asia Healthcare Industry Digest
SEE OTHER BRANDS

The latest healthcare and wellness news from Asia and the Pacific

Asia Healthcare Industry Digest: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Asia Healthcare Industry Digest.

Press releases published on May 19, 2025

Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.

Appili Therapeutics Provides Update on Arrangement with Aditxt, Inc.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, May 19, 2025 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical …

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies

HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid …

ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177

ITM and Radiopharm Sign Supply Agreement for n.c.a. Lutetium-177

GARCHING / MUNICH, Germany and SYDNEY, May 19, 2025 (GLOBE NEWSWIRE) -- ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company, and Radiopharm Theranostics (ASX:RAD; NASDAQ: RADX “Radiopharm”), a developer of a world-class …

Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

Legend Biotech to Host Investor Event During the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

SOMERSET, N.J., May 19, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a live webcast event for investors on Sunday, June 1, 2025, at 6:00 p.m. CT (7:00 p.m. ET) during the …

Recludix Pharma Presents Data Demonstrating Potent Efficacy and High Selectivity of a STAT6 Inhibitor in Preclinical Asthma Model

Recludix Pharma Presents Data Demonstrating Potent Efficacy and High Selectivity of a STAT6 Inhibitor in Preclinical Asthma Model

--Efficacy comparable to anti-IL4/IL13 antibody control --Achieved dose-dependent and durable target modulation in vivo without requiring degradation of STAT6 protein --Avoided broad JAK-mediated immune suppression --Data presented at the American Thoracic …

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

BOSTON and LONDON, May 19, 2025 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop transformational medicines for patients, today announced that members of its …

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair

NORWOOD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical-stage company focused on oncology and obesity, today announced the appointment of Rachelle Jacques as Chair of its Board of Directors, …

Medera Showcased Positive Interim Data From First-in-Human Gene Therapy Trial for HFpEF in Late-Breaking Presentation at Heart Failure 2025 Congress

Medera Showcased Positive Interim Data From First-in-Human Gene Therapy Trial for HFpEF in Late-Breaking Presentation at Heart Failure 2025 Congress

Results from MUSIC-HFpEF Phase 1/2a clinical trial show favorable safety profile and early clinical benefits with SRD-002 gene therapy BOSTON, May 19, 2025 (GLOBE NEWSWIRE) -- Medera Inc. (“Medera”), a clinical-stage biopharmaceutical company focused on …

Alignment Health Plan Recognized as One of Two Medicare Advantage Prescription Drug Plans in the U.S. for Excellence in Pharmacy Quality

Alignment Health Plan Recognized as One of Two Medicare Advantage Prescription Drug Plans in the U.S. for Excellence in Pharmacy Quality

ORANGE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC) has been recognized for excellence in quality for its Medicare Advantage prescription drug (MAPD) plan by the Pharmacy Quality Alliance (PQA). The PQA has measured …

Windtree Therapeutics Announces Istaroxime Presentation at European Society of Cardiology Heart Failure Conference

Windtree Therapeutics Announces Istaroxime Presentation at European Society of Cardiology Heart Failure Conference

WARRINGTON, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on becoming a revenue generating company and advancing early and late-stage innovative therapies …

Eascra Biotech Awarded $100,000 MassVentures START Grant

Eascra Biotech Awarded $100,000 MassVentures START Grant

BOSTON, May 19, 2025 (GLOBE NEWSWIRE) -- Eascra Biotech, a nanomedicine startup, has been awarded a $100,000 Stage I SBIR Targeted Technologies (START) grant funded by the Commonwealth and managed by MassVentures. The funding is to support their work on …

Respira Therapeutics Announces Late-breaking Presentation of RT234 Phase 2b PAH Clinical Trial Results at the American Thoracic Society (ATS) 2025 International Conference

Respira Therapeutics Announces Late-breaking Presentation of RT234 Phase 2b PAH Clinical Trial Results at the American Thoracic Society (ATS) 2025 International Conference

PALO ALTO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Respira Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing RT234 (vardenafil inhalation powder) as the first therapy that pulmonary arterial hypertension (PAH) patients …

Rani Therapeutics Announces Research Agreement with Chugai

Rani Therapeutics Announces Research Agreement with Chugai

- Research agreement is evaluating feasibility of applying Rani’s oral delivery technology to Chugai’s antibodies against undisclosed targets - SAN JOSE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “ …

CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma

CytomX Therapeutics Announces First Patient Dosed in Combination Arm of Phase 1 Study of CX-801 plus KEYTRUDA® (pembrolizumab) in Patients with Metastatic Melanoma

SOUTH SAN FRANCISCO, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that the first patient has been dosed with CX-801 in combination …

Reflect Scientific Strengthens Position in Booming AI Data Center Cooling Market with Patented Cryogenic Innovations

Reflect Scientific Strengthens Position in Booming AI Data Center Cooling Market with Patented Cryogenic Innovations

OREM, Utah, May 19, 2025 (GLOBE NEWSWIRE) -- Reflect Scientific, Inc. (Symbol: RSCF), a pioneer in cryogenic cooling technologies, today highlighted how its patented solutions are uniquely positioned to address the surging global demand for advanced data …

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

aTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International Conference

Blinded baseline demographics and disease characteristics for ongoing Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis largely balanced and representative of targeted trial population. Real-world evidence shows target market for efzofitimod …

Bionano Laboratories Announces a Second Category I CPT Code for OGM Established by the AMA; this one for Use in Whole Genome Analysis for Constitutional Genetic Disorders

Bionano Laboratories Announces a Second Category I CPT Code for OGM Established by the AMA; this one for Use in Whole Genome Analysis for Constitutional Genetic Disorders

SAN DIEGO, May 19, 2025 (GLOBE NEWSWIRE) -- Bionano Laboratories, a wholly-owned subsidiary of Bionano Genomics, Inc. (Nasdaq: BNGO) that offers CLIA-certified laboratory developed tests (LDTs) based on optical genome mapping (OGM), today announced that …

STRATA Skin Sciences Announces Historic Expansion of CPT Codes for Reimbursement of 308nm Excimer Laser Treatments, Unlocking Access for Millions with Inflammatory and Auto-Immune Skin Diseases

STRATA Skin Sciences Announces Historic Expansion of CPT Codes for Reimbursement of 308nm Excimer Laser Treatments, Unlocking Access for Millions with Inflammatory and Auto-Immune Skin Diseases

HORSHAM, Pa., May 19, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to advancing dermatologic care through innovation, announces that the American Medical Association …

Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value

Keros Therapeutics Highlights Commitment to Maximizing Stockholder Value

Files Investor Presentation and Issues Open Letter to Stockholders Urges Stockholders to Protect the Value of Their Investment by Voting “FOR” Each of the Company’s Highly Qualified Director Nominees LEXINGTON, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Keros …

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Alzamend Neuro Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study Taking Place at Massachusetts General Hospital

Topline data expected by year end Head-to-head studies of AL001 versus a marketed lithium carbonate product will be conducted for comparisons of lithium blood and brain/brain-structure pharmacokinetics in healthy subjects ATLANTA, May 19, 2025 (GLOBE …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service